Concordia Healthcare Corp. T.CXR.R

RE: The Jesus of the FDA Must be Short!

[GenericAdvocate]

Donnatal's market share is declining because it is easy to target with its safety concerns. Increasing the price for Donnatal has tried to compensate for the loss in organiz growth. Was Allergan's Viberzi another "unexpected" generic on the market?  There was absolutely zero mention of Viberzi on Concordia's q1 conference call earlier in the year.  Another item for those class action lawyers to sink their teeth into!
Will there be another huge impairment in q3? 

From RBC'S September 2nd IMS Script Tracker:

Donnatal TRx down 2.7% WoW as IBS market continues to face competitive headwinds. Donnatal scripts have seen weakness in the face of Allergan’s Viberzi launch (TRx up 0.1% WoW), which came to market in December 2015. Donnatal NRx were down 3.4% WoW vs. down 0.8% the prior week and TRx were down 2.7% WoW vs. down 0.9% the prior week. Donnatal's current market share (TRx) is 1.6%; Xifaxan holds a 16.2% market share, Viberzi has a 3.8% share, Amitiza has a 27.2% share, and Linzess has a 50.9% share.